Company intelligence / Profile preview
Orion Biotechnology
Ottawa, Ontario, Canadaorionbiotechnology.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company has successfully completed discovery of a first-in-class molecule against CXCR6, an undrugged small protein GPCR for potential immunotherapy treatment for solid tumor cancers. They have two candidates against GPR75 for obesity that have demonstrated efficacy in preclinical evaluations.
- Therapeutic areas
- OncologyEndocrinologyMetabolic Disorders
- Modalities
- PeptidesSmall moleculesProtein-based therapeutics
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Orion Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orion Biotechnology.